- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Coordination compound.
Displaying page 1 of 1.
EudraCT Number: 2017-004087-35 | Sponsor Protocol Number: AVXS-101-CL-304 | Start Date*: 2018-12-21 |
Sponsor Name:AveXis, Inc. | ||
Full Title: A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants with Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy with Multiple Copies of SMN2 | ||
Medical condition: Spinal Muscular Atrophy | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) IT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-004058-11 | Sponsor Protocol Number: RM-493-023 | Start Date*: Information not available in EudraCT |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström syndrome (AS) Patients with Moderate to Severe Obesity | ||
Medical condition: Obesity and hyperphagia in patients with Bardet-Biedl Syndrome or Alström syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2009-013169-24 | Sponsor Protocol Number: PTC124-GD-008-DMD | Start Date*: 2010-01-19 | ||||||||||||||||
Sponsor Name:PTC Therapeutics Inc | ||||||||||||||||||
Full Title: A Phase 2a Study of Ataluren (PTC124) in Nonambulatory Patients with Nonsense–Mutation-Mediated Duchenne/Becker Muscular Dystrophy | ||||||||||||||||||
Medical condition: Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002402-21 | Sponsor Protocol Number: RG_09-205 | Start Date*: 2007-08-24 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma | |||||||||||||
Medical condition: Standard risk hepatoblatoma in children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FR (Ongoing) IE (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
